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Abstract 
Purpose 
The blood brain barrier compromises glioblastoma chemotherapy.  However high 
blood concentrations of lipophilic, alkylating drugs result in brain uptake, but cause 
myelosuppression. We hypothesised that nanoparticles could achieve therapeutic 
brain concentrations without dose-limiting myelosuppression.  
Methods  
Mice were dosed with either intravenous lomustine Molecular Envelope Technology 
(MET) nanoparticles (13 mg kg-1) or ethanolic lomustine (6.5 mg kg-1) and tissues 
analysed.  Efficacy was assessed in an orthotopic U-87 MG glioblastoma model, 
following intravenous MET lomustine (daily 13 mg kg-1) or ethanolic lomustine (daily 
1.2 mg kg-1 - the highest repeated dose possible).  
Myelosuppression and MET particle macrophage uptake were also investigated.  
Results  
The MET formulation resulted in modest brain targeting (brain/ bone AUC0-4h ratios for 
MET and ethanolic lomustine = 0.90 and 0.53 respectively and brain/ liver AUC0-4h 
ratios for MET and ethanolic lomustine = 0.24 and 0.15 respectively).  The MET 
formulation significantly increased mice (U-87 MG tumours) survival times; with MET 
lomustine, ethanolic lomustine and untreated mean survival times of 33.2, 22.5 and 
21.3 days respectively and there were no material treatment-related differences in 
blood and femoral cell counts.  Macrophage uptake is slower for MET nanoparticles 
than for liposomes.  
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Conclusions 
Particulate drug formulations improved brain tumour therapy without major bone 
marrow toxicity.  
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Abbreviations 
CLSM  Confocal Laser Scanning Microscopy 
 
EDTA  Ethylene diamine tetraacetic acid 
 
GBM  Glioblastoma Multiforme  
GCPQ  N-palmitoyl-N-monomethyl-N-N-dimethyl-N,N,N-trimethyl-6-O-glycol 
chitosan 
HPLC  High Performance Liquid Chromatography 
 
MeCN  Acetonitrile 
 
MET  Molecular Envelope Technology 
MRI  Magnetic Resonance Imaging 
 
TFA  Trifluoroacetic acid 
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Introduction 
Glioblastoma multiforme (GBM) is the most frequently occurring primary brain tumour 
in adults (accounting for 65% of primary brain tumours) and is the most aggressive, 
incurable malignancy of the central nervous system (1). GBM continues to be 
associated with poor prognosis, in spite of more recent therapeutic advances, with 
less than a quarter of patients surviving for 2 years after diagnosis (1-3). The median 
survival time is 14 months and only a very small percentage (3 – 5 %) of patients 
survive for more than 3 years (4). As for most cancers, there is no actual cure for 
GBM.  
GBM is characterized by uncontrolled cellular proliferation, diffuse infiltration and 
significant angiogenesis (5) and it is initially diagnosed using magnetic resonance 
imaging (MRI), although image interpretation is sometimes problematic (6). Once 
diagnosed GBM is treated by surgical resection followed by radiotherapy and 
chemotherapy, however, for some tumours there is no acceptable treatment (7, 8).  
Chemotherapy, when indicated, is very challenging due to the heterogeneous and 
infiltrating nature of tumours and therapeutic agents being unable to access the 
tumour site; the latter due to the blood brain barrier (5, 9, 10). Therefore, methods to 
increase the localisation of chemotherapeutics to the intracranial tumour site are 
needed.  Nitrosoureas such as carmustine and lomustine and other alkylating agents, 
e.g.  temozolomide have been employed in GBM chemotherapy, however dose 
limiting toxicities, such as myelosuppression, limit the effectiveness of these drugs 
(11-14).   
It is thus clear that increasing the drug levels at the tumour site while reducing drug 
levels in the bone marrow represent a significant challenge for the chemotherapy of 
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GBM.  One way of achieving high brain concentrations would be to increase the blood 
concentration of the drug via a dose intensification regimen.  In the case of a lipophilic 
drug, we hypothesise that nanoparticles may allow high drug concentrations to be 
administered (dose intensification) such that high blood concentrations, and thus high 
brain tumour levels, of these drugs are achieved, without delivering high doses to the 
bone marrow.  Dose intensification has been attempted in patients but requires 
autologous peripheral blood stem cell (PBSC) support via PBSC infusions (15).   
We have chosen to test this bone marrow avoidance hypothesis with a class of 
nanoparticles which are known to evade liver capture on intravenous injection (16).  
These Molecular Envelope Technology (MET) nanoparticles are constructed from N-
palmitoyl-N-monomethyl-N,N-dimethyl-N,N,N-trimethyl-6-O-glycol chitosan, a self-
assembling polymer amphiphile (17). Drug loaded MET formulations were prepared 
and their biodistribution and pharmacodynamics/ toxic effects studied.  We sought to 
provide a mechanistic explanation by also studying macrophage uptake of the MET 
particles.  
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Materials and Methods 
Materials 
All materials were obtained from Sigma Aldrich Corporation, MO, USA, unless 
otherwise stated.  All solvents were obtained from Fisher Scientific, UK, 
Loughborough, United Kingdom. 
Cell Culture 
U-87 MG human glioblastoma cell line was purchased from American Type Culture 
Collection (ATCC® HTB-14™; ATCC, Manassas, VA, USA). U-87 MG cells were 
grown in Minimum Essential Medium (Life Technologies, Paisley, UK) supplemented 
with FBS (10 % v/v; Labtech International Ltd, Uckfield, East Sussex, UK); sodium 
pyruvate (1 mM; Life Technologies) and L-Glutamine (2 mM; Life Technologies). Cells 
were maintained in culture (37oC in 5 % CO2) for up to 14 days (splitting every 2 – 3 
days when 75 – 80% confluence was reached in the 75 cm2 tissue culture flask) before 
they were used for tumour implantation.  
 Synthesis of the MET polymer 
The MET polymer was synthesised as previously described (17).  The characteristics 
of the MET polymer are shown in Table 1. 
Preparation of MET Lomustine Nanoparticles  
The nanoparticle formulation was prepared by probe sonicating lomustine (2 mg ml-1), 
MET polymer (20 mg ml-1) soybean oil (10 mg ml-1) and polysorbate 80 (5 mg ml-1) in 
dextrose solution (5 % w/v) on ice for 30 minutes (MSE Sonipreo 150, MSE UK, with 
the instrument set at 50 % of its maximum output). Each time 26 ml of the MET 
formulation was prepared.  The formulation was filtered (0.22 µm) and the amount of 
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lomustine encapsulated was measured by HPLC. To achieve high drug 
concentrations, the formulation from above (26 ml) was lyophilised and reconstituted 
to 13 ml using double deionised water (Millipore Water Purification System, EMD 
Millipore Corporation, Merck KGaA, Darmstadt, Germany).  Formulations were 
analysed by HPLC using an analytical C18 derivatised silica gel based (Onyx 
Monolithic: 5 μm; 100 x 4.6 mm; Phenomenex®, UK) column using an Agilent (Agilent 
Technologies 1200 Series) HPLC system.   
Formulations were sized using a Malvern Nanosizer (Malvern Instruments, Malvern, 
UK) at a temperature of 25°C and data analysed using the Contin method of analysis.   
Formulations were imaged using transmission electron microscopy (TEM). For TEM 
imaging, a drop of the formulation was placed on a formvar/carbon coated grid and 
excess sample was blotted off on a filter paper (Whatman No 1). The samples were 
then negatively stained (uranyl acetate 1 % w/v) and left for 1 – 2 minutes to air dry. 
Subsequently, images were captured on the TE microscope using an AMT digital 
camera (5 mega pixels; AMT Deben, UK Ltd).  
The stability of the dried lomustine nanoparticles was studied over a 7-day period, with 
formulations stored at room temperature and reconstituted periodically to produce a 1 
mg ml-1 lomustine formulation, the drug content analysed and the particle size 
measured as described above. 
Preparation of the Lomustine Ethanolic Formulation 
The ethanolic lomustine formulation administered to male CD-1 mice as control in the 
pharmacokinetic studies was prepared as follows: 5 µl of polysorbate 80 was 
transferred into a glass vial containing 2 mg lomustine. The vial was vortexed for 1 
minute and 895 µl of 5 % w/v dextrose solution was added to it. The vial was vortexed 
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for another 1 minute. It was then sonicated on ice for 30 minutes as described above. 
100 µl of 10 % v/v ethanol was added to the vial containing the lomustine, polysorbate 
80 and 5 % w/v dextrose solution and was vortexed for 1 minute. The content of the 
vial was filtered through a 0.22 µm syringe filter (Millipore).  
The ethanolic lomustine formulation administered as control in the pharmacodynamics 
and toxicity studies was prepared by vortexing lomustine (2 mg) in absolute ethanol 
(100 µl) with polysorbate 80 (5 mg ml-1) in 5 % w/v dextrose solution (final ethanol 
concentration of 10 % v/v). The resulting colloidal mixture was then filtered (0.22 µm; 
Millipore syringe filter) to remove drug crystals and yield a non-particulate formulation.  
The lomustine content of the formulations was determined by HPLC analysis of the 
filtrate.  
Animals 
Ethics Statement 
All animals were housed at the UCL School of Pharmacy’s Biological Services Unit 
(BSU) and were acclimatized in the BSU for 5 – 7 days before studies commenced. All 
animal studies were conducted in accordance with the policies and regulations of the 
Home Office as stipulated in the Animals and Scientific Acts 1986 UK, for the handling 
and care of laboratory animals used in scientific research, the recommendations of the 
BSU and with the approval of the ethics committee.  
Pharmacokinetics 
The MET lomustine formulation (1.04 mg ml-1) was intravenously administered to 
healthy male CD 1 mice (22 - 28 g) via the tail vein at a dose 13 mg kg-1 and in a dose 
volume of 289 – 357 μl. Control animals were administered an ethanolic lomustine 
formulation (0.37 mg ml-1) at a dose of 6.5 mg kg-1 and in a dose volume of   370 – 
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490 μl. Animals were killed at various time points and the blood, brain, liver and bone 
were sampled and the solid tissues stored at -80°C until analyses could be performed 
on them.  Plasma was obtained by centrifugation of the blood samples (4000g, Hermle 
Z 323K centrifuge, HERMLE Labortechnik GmbH Siemensstr. 25 D-78564 Wehingen, 
Germany) at 4°C for 10 minutes and the plasma stored at -20°C until analyses could 
be performed.  
Tissue Analysis 
To thawed plasma samples (0.2 ml) was added chilled homogenising buffer [trizma 
HCl (50 mM), ethylene diamine tetraacetic acid [(EDTA); (0.1 mM), pH = 2, 0.2 ml], 
and carmustine (20 µg ml-1; 0.1 ml) as internal standard. This mixture was extracted 
with ethyl acetate (3 X 5 ml) and centrifuged (1000g) for 10 minutes at 4 oC. The 
combined organic layers were evaporated to dryness under a stream of nitrogen.  
For analysis of brain, liver and bone samples, each tissue was weighed and 
homogenised in homogenising buffer (1 ml) and the homogeniser rinsings (2 X 1 ml) 
added to the homogenate.  Carmustine (20 µg ml-1; 0.1 ml) was added to the aqueous 
layer as an internal standard and the homogenate extracted with ethyl acetate (3 X 10 
ml). The mixture was centrifuged (1000g) for 10minutes at 4 oC and the combined 
organic layers evaporated to dryness under a stream of nitrogen. The residues were 
subsequently reconstituted in mobile phase [acetonitrile (MeCN; HPLC grade): 0.02 % 
v/v trifluoroacetic acid (TFA) in water (H2O): - 50: 50, 0.2 ml].  The reconstituted 
extracts were then subjected to HPLC analysis.   
Analysis for lomustine content in the tissue samples was carried out using gradient 
elution method with an initial condition of 15 % MeCN and proceeding to 65% over 10 
minutes. The mobile phase was 50:50 (0.02 % v/v TFA in H2O: MeCN) at a flow rate of 
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2 ml min-1. The extracted samples were injected (20 µl) over an onyx monolithic C18 
(5 µm, 100 x 4.6 mm) Phenomenex® column set at 40°C.  Lomustine content was 
detected using a UV detector set at 230 nm. Calibration plot was done for plasma, 
brain, bone marrow and liver from which the actual concentration of lomustine in the 
samples was obtained. All results were expressed as mean ± standard deviation.  
The pharmacokinetic parameters for the MET nanoparticle lomustine formulation was 
obtained using the non-compartmental method of the WinNonlin® software, version 4.1 
(Pharsight Corporation, California 94040, USA).  
Ex-Vivo Coherent Anti-Stokes Raman Spectroscopy (CARS) Imaging 
Deuterated N-palmitoyl-N-monomethyl-N-N-dimethyl-N,N,N-trimethyl-6-O-glycol 
chitosan (MET) polymer was synthesised as previously described (18) and deuterated 
MET particles prepared as previously described (18). Male CD-1 mice (25-30 g) were 
intravenously dosed with deuterated MET particles (10.4 mg ml-1) at a dose of 75 mg 
kg-1 and in a dose volume of 200 μl. Animals were killed 1 hour after dosing. The 
subsequently harvested brains were stored in neutral buffered formalin (10 % v/v).  
Fixed brains were cut into 0.5 mm thickness coronal slices with razor blades using a 
brain matrix (Zivic instruments, Pittsburgh, PA, USA). Brain slices were placed 
between two glass coverslips and sealed against dehydration prior to imaging using 
CARS microscopy, as previously described (19). 
Bone Marrow Toxicity 
Male CD-1 mice were randomly assigned to treatment groups and intravenously 
administered (via the tail vein) either MET lomustine (2.02 mg ml-1) at a dose of 13 mg 
kg-1 in a dose volume of ≈ 200 μl or ethanolic lomustine (0.16 mg ml-1) at a dose of 1.2 
mg kg-1 in a dose volume of ≈ 200 μl daily for 10 consecutive days.   
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Subsequently, mice were killed on 1, 7, 14, 21 or 30 days after completion of the 
dosing and blood and femoral marrow cell counts were assessed to determine the 
effect of the treatments on the bone marrow.  
Blood samples were obtained by cardiac puncture and transferred into EDTA coated 
tubes (BD Microtainer® tube with Dipotassium EDTA; Becton, Dickson and Company, 
New Jersey, USA). Full blood counts were carried out using an automatic 
haemocytometer (Sysmex Automated Haematology Analyzer KX- 21, Sysmex 
Corporation, Chuo-ku, Kobe 651-0073, Japan) to determine the levels of the various 
blood components (white blood cells, red blood cells and platelets). Femoral cells 
were obtained by flushing out the bone marrow with 1 ml PBS and the cell counts 
were determined by flow cytometry (MACSQuant Analyzer, Miltenyi Biotec, GmbH, 
Germany). 
Macrophage Nanoparticle Uptake 
Nile Red Loaded MET Nanoparticles 
MET Nile Red formulations for flow cytometry studies were prepared by probe 
sonicating (QSonica sonicator, Connecticut, USA) Nile Red (50 µg ml-1) and the MET 
polymer (1 mg ml-1) in dextrose solution (5 % w/v) on ice for 30 minutes, with the 
instrument set at 25 % of its maximum output. This was followed by centrifugation 
(1000g) for 30 minutes at 4 oC to separate free Nile Red from encapsulated Nile Red. 
The supernatant was then carefully collected immediately after centrifugation. MET 
Nile Red formulations for confocal laser scanning microscopy (CLSM) experiments 
were prepared by adding a solution of Nile Red (100 µg ml-1, 100 µL) in ethanol to a 
dispersion of the MET polymer (1 mg ml-1) in dextrose solution (5 % w/v), to a final 
volume of 10 ml and probe sonicated on ice for 30 minutes, with the instrument set to 
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25 % of its maximum output. This was followed by centrifugation (1000g) for 30 
minutes at 4 oC to separate free Nile Red from encapsulated Nile Red. 
Nile Red Loaded Liposomes 
Nile Red (50 µg ml-1), egg phosphatidyl choline (3 mg ml-1) and cholesterol (1.4 mg ml-
1) were dissolved in chloroform (10 ml) and the resulting solution evaporated to 
dryness at 40 °C using a rotary evaporator. The thin lipid film obtained was then 
hydrated with 5 % w/v dextrose solution (5 ml) by shaking for 30 minutes at room 
temperature to yield a homogenous dispersion of egg phosphatidyl choline liposomes. 
This dispersion was subsequently probe sonicated on ice for 15 minutes, as described 
above.  The liposome formulation was then centrifuged (1000g) for 30 minutes at 4 oC 
to eliminate free unencapsulated Nile Red and the supernatant was carefully collected 
immediately after centrifugation.  These liposomes were used for the flow cytometry 
studies.   
Liposomal Nile Red formulations for CLSM imaging were prepared by adding a Nile 
Red solution (100 µg ml-1, 100 µL) in chloroform to egg phosphatidyl choline (3 mg ml-
1) and cholesterol (1.4 mg ml-1) dissolved in chloroform (10 ml) and following the 
methodology outlined above. 
For both the Liposome and MET Nile Red formulations used for CLSM, the 
concentration of Nile Red [determined by fluorimetry, λexc = 488 nm and λem = 655 
nm, (LS – 50 B, Perkin Elmer Inc., USA Spectrofluorimeter, with FL WinLab (Perkin 
Elmer Inc, USA) software] was adjusted so that both formulations had the same Nile 
Red concentrations (0.2 µg ml-1) prior to application to the cells.  
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Cell uptake Experiments 
J774A.1 cells were cultured in Dulbecco's Modified Eagle's Medium [(DMEM; ATCC® 
30-2002™) modified to contain L-glutamine (4 mM), glucose (4.5 g L-1), sodium 
pyruvate (1 mM), and 1500 mg L-1 sodium bicarbonate] supplemented with 10 % fetal 
bovine serum. The cells were maintained in culture for at least 14 days before they 
were used for uptake experiments. For flow cytometry and confocal imaging, cells 
were handled according to methods described by Fernando et al 2010 (20) and Kim et 
al 2012 (21) with some modifications, as outlined below.  
Cells were seeded in 6 well plates at a density of 300,000 cells per well and incubated 
for 72 hours.  Cells were then treated with either MET Nile Red (0.3 µg ml-1) or the 
liposome Nile Red (0.4 µg ml-1) formulations with some wells left untreated as control. 
Cells were treated for predetermined time periods of 5 minutes, 10 minutes, 30 
minutes, 1 hour, 2 hours, or 4 hours. Cells were then washed 3 times with cold 
Dulbecco’s phosphate buffered solution (DPBS, [calcium chloride anhydrous (CaCl2; 
0.9 mM), magnesium chloride (MgCl2.6H2O; 0.5 mM), potassium chloride (KCl; 2.7 
mM, potassium phosphate monobasic (KH2PO4; 1.5 mM), sodium chloride (NaCl 
137.9 mM), sodium phosphate dibasic (Na2HPO4.7H2O; 8.1 mM), pH 7.0 – 7.2] (2 ml / 
well) and then incubated in cold PBS – EDTA (PBS- EDTA, [KH2PO4 (1.9 mM), NaCl 
(138.9 mM), Na2HPO4.2H2O (6.6 mM), Titriplex III (EDTA Na2; 1.4 mM), lithium 
chloride (LiCl; 10.1 mM); pH 7.5)] (1 ml / well) for 1 – 2 minutes. Cells were then 
harvested by gently scraping and pipetting the cell suspension which was then 
centrifuged and suspended in cold Ringers solution [Sodium chloride (38.5 mM), 
Potassium chloride (1.4 nM), Calcium chloride hexahydrate (0.5 mM), Sodium 
bicarbonate (0.6 mM); pH 7] and the nanoparticle uptake was quantified using the flow 
cytometer (MACSQuant Analyzer, Miltenyi Biotec, Germany) with uptake quantified 
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with reference to the Nile Red fluorescence. A total of 20,000 cells were measured in 
each sample within the Nile Red positive channel. The experiment was carried out in 
quadruplet for each formulation and the untreated control cells. 
For confocal microscopy imaging, cells were seeded in glass bottom 35 mm tissue 
culture dishes (MatTek, Corporation, Ashland, MA, USA) at a density of 75,000 cells 
per dish and incubated for 48 hours. Cell uptake of the formulations was then 
monitored in a time-lapse experiment set up on a Zeiss LSM 710 laser scanning 
microscopy imaging unit (LASOS Lasertechnik GmbH, Carl Zeiss, Franz-Loewen-
Straße 2, 07745 Jena, Germany). Images were captured 3 minutes after treatment 
with the formulation and subsequently after every 5 minutes. The images were 
analysed using Zen 2009 software (Carl Zeiss Microscopy GmbH Carl Zeiss 
Promenade 10, 07745 Jena, Germany). 
Brain Tumour Studies 
Brain Tumour Model and Magnetic Resonance Imaging 
Tumour bearing mice brains were embedded in a mixture (50: 50) of agarose gel (1 % 
w/v) and formaldehyde solution (4 % w/v) prior to imaging, to fix the tissue and minimize 
shifting of the samples during measurement. Images were collected using a 1.5 T 
Philips Intera Gyroscan magnet (Philips Healthcare, 5680 DA Best, The Netherlands). 
A high resolution T2-weighted Turbo Spin-Echo (TSE) sequence was used (Repetition 
time (TR) = 3000 ms, Echo time (TE) = 110 ms, flip angle = 90 degrees, number of 
slices = 54, voxel size = 0.14 X 0.14 X 0.14 mm3, 10 averages). High-resolution 
images were achieved by utilizing a microscopy coil, diameter 23 mm. 
Image parameters were established in a preliminary experiment, so as to optimize 
tumour edge detection.  OSIRIX software (Pixmeo SARL, Switzerland) was utilized to 
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analyse the MRI images and to measure the tumour volume, after a manual 
determination of the edges in a slice-by-slice process.    
Brain Tumour Treatment 
Human glioblastoma (U-87 MG) cells were cultured in Minimum Essential Medium 
(MEM) supplemented with foetal bovine serum (FBS, 10 % w/v); sodium pyruvate (1 
mM; 5 ml) and L-Glutamine (1 % w/v; 5 ml). Cells were maintained in culture for up to 
14 days before they were used for tumour implantation. 
Intracranial tumour models were established by orthotopic implantation of the 
glioblastoma cells (100,000 cells) in the left striatum (+ 0.5 mm anterior, – 2 mm lateral 
and to a depth of 3mm to the bregma, determined by a BENCHmark™ digital 
stereotaxic control panel), of stereotactically fixed anaesthetised (inhaled isoflurane) 
female CD-1 nude mice (20 – 30g in weight). Once tumours were established (7 days 
after implantation) mice were randomly assigned to treatment groups and injected 
daily (tail vein) with the lomustine formulations.  Animals were either dosed with MET 
lomustine (2.6 mg ml-1) at a dose of 13 mg kg-1 and a dose volume of ≈ 200 µL or 
were dosed with ethanolic lomustine (0.18 mg ml-1) at a dose of 1.2 mg kg-1 and a 
dose volume of ≈ 200 µL.  Animals were dosed on 10 consecutive days and the dose 
of the ethanolic lomustine formulation was the maximum dose volume that could be 
administered with repeat dosing.  Animals were weighed daily and animals were killed 
once body weight had declined by 15 % compared to the start of treatment.  
Examination of control animals once body weight had reached this threshold value 
revealed tumours which were 83.4 – 98.1 mm3 in volume, with a mean volume of 91.8 
± 7.57 mm3    
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Statistics 
Data were subjected to a one-way analysis of variance (ANOVA) with Tukey post hoc 
test using SPSS, version 17.0 software (SPSS Inc., Chicago, IL 60606-6307) for the 
pharmacokinetics experiment and Minitab® 16 software (Minitab, Inc., Pennsylvania, 
USA) for the brain tumour and bone marrow toxicity experiments. The treatment 
groups were compared two groups at a time for each time point and the significance 
level was set at 0.05. 
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Results 
Synthesis of the MET Polymer 
Table 1 – MET Polymer Characteristics 
Batch Number Mole% 
palmitoyl 
groups 
Mole% 
quaternary 
ammonium 
groups 
Molecular Weight 
Mw 
(kDa) 
Mn 
(kDa) 
Polydispersity 
GCPQOO28072009 
GCPQOO18082009 
GCPQOO28112009 
GCPQSR11112011 
GCPQFF18042012 
GCPQFF20022013 
GCPQFF26032013 
 
 
26.2 
26.6 
22 
21.9 
23.7 
19.1 
23.4 
 
11.1 
6.2 
8 
12.4 
13.2 
13.5 
14.4 
 
* 
* 
* 
8.4 
9.5 
9.3 
10.2 
* 
* 
* 
7.8 
8.6 
7.8 
6.5 
* 
* 
* 
1.1 
1.1 
1.2 
1.6 
 
*= The molecular weight of these polymers is in the region of 9 – 10 kDa from other 
studies (17, 22). 
Nanomerics’ MET is based on the self-assembling polymer N-palmitoyl-N-
monomethyl-N,N-dimethyl-N,N,N-trimethyl-6-O-glycol chitosan, which assembles into 
nanoparticles in aqueous media (17, 22). Various batches of the MET polymer were 
synthesised and characterised (Table 1). 
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Preparation of MET Lomustine Nanoparticles 
The nanoparticle formulations presented as translucent liquids with a z-average mean  
   
Figure 1: TEM image with negative staining of a lomustine formulation containing 
lomustine (2 mg ml-1), soya bean oil (10 mg ml-1), polysorbate 80 (5 mg ml-1), MET 
polymer batch GCPQOO28112009 [(mol % palmitoylation = 22 and mol % 
quaternisation = 8 %; 20 mg ml-1)] in dextrose (5% w/v).  Formulations were 
prepared by reconstituting a freeze dried sample containing 0.77 mg ml-1 lomustine 
to half its original volume.    
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particle size of 336 ± 0.44 nm and a polydispersity of 0.5. The formulations were 
relatively polydisperse. Nanoparticles were spherical, presumably consisting of 
lomustine filled oil droplets in an oil in water formulation (Figure 1) as well as MET 
polymer and polysorbate 80 micelles.  The oil droplets were stabilised by the MET 
polymer and polysorbate 80.  The oil droplets/ micelles (it was not possibly to 
 
Figure 2: The stability of MET-lomustine nanoparticle 
formulations when stored as the freeze dried cake at room 
temperature.  Formulations were reconstituted in water 
prior to analysis and no crystals were observed after 
reconstitution.  
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conclusively distinguish both particle types using electron microscopy) varied in size 
from as little as 50 nm to up to 600 nm in size.  Although the majority of the oil droplets 
and micelles were below 100 nm in size, the PCS method of particle size analysis is 
heavily weighted towards the larger sized particles.  This is the first report of 
Nanomerics’ MET acting as a stabiliser of emulsion formulations and forming 
nanoemulsions.   
The nanoemulsions were stable for up to 8 days when stored dry at room temperature 
and could be reconstituted into nanoemulsions (Figure 2), with no sign of drug crystal 
formation (data not shown).  
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Ex-Vivo CARS Imaging  
CARS microscopy imaging detects clusters of polymer molecules. The intensity of the 
CARS signal scales quadratically with the concentration of bonds being probed within 
the focal volume (23). Therefore, clusters of polymers in a single nanoparticle will 
generate significantly higher signal than individual polymer molecules. The signal 
 
Figure 3: Epi-detected CARS microscopy image 
illustrating the distribution of deuterated MET 
nanoparticles within a mouse brain blood vessel, 
from a sample harvested 1 hour after intravenous 
injection of deuterated MET nanoparticles (75 mg 
kg-1). The pump and Stokes wavelengths were 
tuned to probe the C-D resonance at 2100 cm-1 
(green contrast) and the C-H resonance at 2845 
cm-1 (red contrast). 
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strength of the carbon-deuterium CARS signal in figure 3 was several orders of 
magnitude greater than the non-resonant background, and therefore was indicative of 
nanoparticles, rather than individual polymer chains (24). 
The deuterium labelled MET nanoparticles were visualised in ex-vivo brain samples 
after intravenous injection and were found to adhere to the brain endothelium, i.e. to 
the luminal side of the blood brain barrier (BBB).  The MET polymer CARS signal was 
not seen in the brain parenchyma and as previously reported particles appear to 
adhere to the BBB (19) and are not delivered to the brain (16).  However, MET 
nanoparticles are delivered to the BBB, adhere to the brain endothelial cells (Figure 
3), from where they presumably release loaded drug for transport across the BBB. 
Pharmacokinetics 
Following intravenous administration, plasma levels of lomustine were relatively low 
with less than 1 % of administered dose detected in the plasma after 5 minutes (Figure 
4). Lomustine is rapidly distributed to tissues and metabolised and is not normally 
detected in the plasma (25). 
The MET formulation improves the delivery of lomustine to the brain by 2 fold by 
enabling a higher dose to be administered.  Brain levels were similar to plasma levels 
for all formulations, evidence of good across BBB transport for the drug (Figure 4, 
Tables 2, 3 and 4).  Additionally, when compared to an ethanolic formulation of the 
drug at a dose of 6.5 mg kg-1, the MET nanoparticles reduce the exposure (AUC0 – 4h) 
of the bone (which includes the bone marrow) and liver to lomustine by 25 % and 38 
% respectively, whereas brain exposure (AUC0 – 4h) for both formulations is similar 
(Figure 4 and Table 2).  The Cmax of the bone is also higher for the 6.5 mg kg-1 
ethanolic formulation when compared to the 6.5 mg kg-1 MET formulation (Figure 4d, 
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Table 4).  A doubling of the lomustine dose by administering lomustine in the form of 
the MET formulations (6.5mg kg-1 ethanolic lomustine injection vs 13 mg kg-1 MET - 
lomustine) results in virtually no change in the plasma AUC0-120, presumably because   
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Figure 4: The biodistribution of MET - lomustine nanomedicine formulations: a = 
plasma, b = brain, c = liver, d = bone (including bone marrow),  = MET – 
lomustine (13 mg kg-1),  MET - lomustine (6.5 mg kg-1),  = ethanolic 
lomustine (6.5 mg kg-1).  The MET formulation improves the delivery of 
lomustine to the brain by 2 fold by enabling a higher dose to be administered.  
Additionally, when compared to an ethanolic formulation of the drug at a dose of 
6.5 mg kg-1, the MET nanoparticles reduces the exposure (AUC0 – 4h) of the 
bone marrow and liver to lomustine by 25% and 38% respectively, * = significant 
difference between the high dose MET formulation (13 mg kg-1) and all other 
formulations (p < 0.05), # = significant difference between ethanolic formulation 
and both MET formulations (p < 0.05), § = significant difference between low 
dose MET formulation (6.5 mg kg-1) and all other formulations (p < 0.05).  
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Table 2: Lomustine Tissue AUC0-120 Following Intravenous Dosing 
Formulation and 
Dose 
Dose Brain 
AUC0-120min 
(g g-1 
min) 
Bone 
AUC0-120min 
(g g-1 
min) 
Liver 
AUC0-
120min 
(g g-1 
min) 
  
MET - Lomustine  13 mg kg-1 44.06 49.03 187.18 0.899 0.235 
Ethanolic 
lomustine  
6.5 mg kg-1 21.54 40.89 141.10 0.527 0.152 
MET - Lomustine  6.5 mg kg-1 17.28 30.79 87.64 0.561 0.197 
 
Table 3: Lomustine Plasma AUC0-120 Following Intravenous Dosing 
Formulation MET - Lomustine  Ethanolic lomustine  MET - Lomustine  
Dose 13 mg kg-1 6.5 mg kg-1 6.5 mg kg-1 
Plasma  
AUC0-120  
(g ml-1 min)  
48.35 48.21 48.33 
 
0.91 0.45 0.36 
 
3.87 2.93 1.81 
 
1.01 0.848 0.637 
 
 
 
  
  
Brain AUC
0-120min
Bone AUC
0-120min
  
Brain AUC
0-120min
Liver AUC
0-120min
  
Brain AUC
0-120min
Plasma AUC
0-120min
  
Liver AUC
0-120min
Plasma AUC
0-120min
  
Bone AUC
0-120min
Plasma AUC
0-120min
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Table 4: Lomustine Cmax Values 
Formulation Dose  
(mg kg-1) 
Plasma  
(μg ml-1) 
mean ± s.d 
Brain  
(μg g-1)  
mean ± s.d 
Liver  
(μg g-1) 
mean ± s.d 
Bone  
(μg g-1) 
mean ± s.d 
MET lomustine 13 1.84 ± 0.43* 2.74 ± 0.67* 9.85 ± 1.32* 1.82 ± 0.31 
Ethanolic lomustine 6.5 0.84 ± 0.32 1.24 ± 0.40 3.00 ± 1.33 1.46 ± 0.15 
MET lomustine 6.5 0.70 ± 0.15 0.76 ± 0.27 2.12 ± 0.98 0.78 ± 0.34* 
* = significant differences between formulation and all other formulations (p < 0.05)  
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lomustine is extensively distributed and metabolised in the plasma (25), but does lead 
to a proportional increase in brain AUC0-120 values (2.2 fold) and a limited increase in 
both bone (1.2) and liver (1.3) AUC0-120  values (Table 2 and 3).  
At the highest dose, MET lomustine delivers 0.33 % (0.77 % per gram of brain) of the 
dose to the brain.  It is clear that the MET formulation produces higher brain levels, 
while sparing the bone marrow and liver and this altered distribution is not 
underpinned by an increase in plasma exposure (as is seen with other pharmaceutical 
particulates such as liposomes (26, 27)) but is due to differential tissue uptake 
mechanisms. 
Animals administered 6.5 mg kg-1 lomustine either as the MET or ethanolic formulation 
showed no difference in the drug’s plasma and brain Cmax, whereas the ethanolic 
formulation produced a significantly higher Cmax in the bone (including the bone 
marrow), when compared to the MET formulation (Figure 4, Table 4), we thus 
conclude that the MET particles avoid the bone and bone marrow.  Furthermore, with 
the 6.5 mg kg-1 dose, the MET particles are cleared faster from the liver when 
compared to the drug injected as an ethanolic solution (Figure 4c) and we thus 
conclude that the MET particles are not retained by the liver.  Lomustine 
chemotherapy is associated with dose limiting myelosuppression (15, 28-30) and 
hepatotoxicity in dogs (31).  Myelosuppression and hepatotoxicity are thus dose 
limiting adverse effects for the drug and any formulation that minimises bone marrow 
and liver exposure should have a positive impact on treatment.   
Bone Marrow Toxicity 
Following the observation that the MET formulation delivered proportionately less 
lomustine to the bone and bone marrow, an assessment of bone marrow toxicity was  
 29 
 
carried out (Figure 6) after chronic dosing of either MET lomustine (13 mg kg-1) or an 
ethanolic formulation of lomustine at the highest dose possible with multiple dosing 
(1.2 mg kg-1).   
 
 
Figure 6: Mice blood cell counts and haemoglobin assessments following 10 daily 
doses of lomustine formulations: white bar = control animals, grey bar = ethanolic 
lomustine formulation (1.2 mg kg-1), black bars = MET lomustine (13 mg kg-1), * = 
statistically significantly different from all formulations, § = statistically significantly 
different from control animals (untreated).  
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Full femoral cell counts (Figure 6a) and white blood cell counts (Figure 6d) remained 
unchanged for both formulations.  
There were minor changes in red cell count (83.0 ± 8.0% of control values) and 
haemoglobin levels (84.5 ± 3.5% of control values) with the high dose (13 mg kg-1) 
MET formulation (Figures 6b and 6e) on Day 1 with recovery after 7 days for the red 
cell count and recovery after 30 days for the haemoglobin levels. The changes in 
haemoglobin levels are unlikely to be clinically significant as the range of acceptable 
values for haemoglobin [male 14 – 18 g/dL; female 12 – 16 g/dL  (32) spans at least a 
± 20 % range.  
The main myelosuppressive changes were detected in the platelet count, with platelet 
levels falling for both the low dose ethanolic (1.2 mg kg-1) and high dose MET (13 mg 
kg-1) formulation treated groups (Figure 6c).  The nadir values for both groups were 
recorded on Day 7 with platelet nadir values of 56 % and 79 % of the control values 
recorded for the high dose MET (13 mg kg-1) and low dose (1.2 mg kg-1) ethanolic 
formulations respectively. For the ethanolic formulation treated animals, recovery was 
observed after 14 days while the higher dose MET nanoparticle treated group showed 
recovery after 21 days.  In essence the administration of ten times the ethanolic dose 
as a MET formulation resulted in very little additional haematological toxicity when 
compared to the low dose ethanolic formulation. 
Macrophage Uptake 
Macrophages are a heterogeneous group of cell types, which are resident in a number 
of tissues, including the bone marrow and the liver; with one of their functions being 
the removal of particulate cellular debris (33).  In order to understand the mechanisms 
underpinning the low liver, bone and bone marrow drug levels, we hypothesised that 
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the main mechanism could lie with a reduced uptake of the MET nanoparticles by the 
macrophages in the liver and bone marrow.  Previously we have shown that on 
intravenous injection, liver deposition is comparatively low for MET nanoparticles, with 
only 4 % of the intravenous dose found in the liver 10 minutes after dosing (16), 
compared to peak levels of 67% of the intravenous dose of liposomes found in the 
liver 80 minutes after dosing (34).  We hypothesised that the low liver uptake of MET 
nanoparticles could be due to the low uptake by liver macrophages and it is 
conceivable that the bone levels may also be reduced due to low bone marrow 
macrophage uptake.  
In vitro within the J774A.1 cell line, the uptake of liposomal Nile Red is rapid with 89 % 
of cells positive for Nile Red within 10 minutes of incubation (Figure 7a).  While MET 
nanoparticles are also taken up by macrophages, uptake is significantly slower with 71 
% of cells positive for MET Nile Red one hour after incubation.  Uptake as opposed to 
a simple cell surface association was verified by confocal laser scanning microscopy, 
which shows the Nile Red signal at the level of the nucleus (Figures 7b and 7c).    
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The rate of macrophage uptake is thus slower for the MET nanoparticles when 
compared to the uptake by liposomes and it is thus possible that the reduced liver and 
bone and bone marrow drug levels and consequent relatively mild effect on the bone 
marrow of the dosage form could be the result of reduced macrophage uptake. The 
macrophage uptake data thus provides further proof that the MET nanoparticles 
appear not to be taken up by the reticuloendothelial system to an appreciable extent.   
 
 
 
 
 
 
Figure 7a: The uptake of Nile red loaded particles in the J774A.1 cell line (a 
macrophage cell line).  Cells were treated with Nile red loaded MET nanoparticles 
or Nile red loaded liposomes at a Nile red concentration of 0.3 µg ml-1 and 0.4 µg 
ml-1 respectively.  The cells were washed to remove excess formulation was prior 
to analysis. 
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Figure 7b: Confocal laser scanning microscopy image of J774A.1 cells following 
incubation with MET Nile Red particles (0.2 µg ml-1) for 18 minutes.  Figure 7c: 
Confocal laser scanning microscopy image of J774A.1 cells following incubation with 
liposomal Nile Red (0.2 µg ml-1) for 18 minutes.  Scale bar = 10 µm.  
 
 
 
 
 
 
 
 
 
 
b c 
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Brain Tumour Model  
U-87 MG intracranial tumours were successfully established and imaged by MRI 
(Figure 8). 
 
  
Figure 8: Magnetic resonance T2 weighted images of 
an established intracranial tumour. 
 35 
 
   
Brain Tumour Treatment 
Animals with established tumours (7 days after implantation of the U-87 MG cells) 
were treated for 10 consecutive days, with treatment commencing on Day 7 and 
concluding on Day 16.  The mean survival time for animals that received the MET 
lomustine (13 mg kg-1 per day) formulation was 33.17 days, while untreated control 
animals had a mean survival time of 21.33 days (Figure 9a II). A comparable mean 
survival time (31 days) was obtained for the MET lomustine formulation treated 
animals in a previous (first) study. The untreated control animals in the first study had 
a mean survival time of 17.14 days (Figure 9a I). Animals that received the ethanolic 
lomustine (1.2 mg kg-1) formulation of the drug had similar mean survival times of 22 
and 22.5 days in the first and second studies respectively (Figure 9a I and II). The 
dose of lomustine (1.2 mg kg-1) administered in the ethanolic formulation was limited 
by the poor aqueous solubility of lomustine and was the dose achievable with multiple 
dosing when lomustine was formulated in 10 % v/v ethanol containing polysorbate 80 
(5 mg ml-1). 
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Figure 9a I (top- first study) and II (bottom- second study): Survival plots of female CD-
1 mice bearing an intracranial U-87 MG tumour, following treatment with: a) MET 
lomustine (13 mg kg-1 per day 2.6 mg ml-1, dose volume = ≈ 200 µL, black filled 
symbols), b) ethanolic lomustine (1.2 mg kg-1 per day; 0.18 mg ml-1, dose volume = ≈ 
200 µL, grey filled symbols) or c) untreated (unfilled symbols).  Mice were killed once 
body weight had declined by 15 % compared to the start of treatment.  Mice were 
administered 10 doses with treatment commencing on Day 7 and treatment concluded 
on Day 16. 
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During treatment the animals’ body weight was monitored and there was no significant 
difference between the body weights when all groups were compared (untreated, 
ethanolic and MET treated animals – Figure 9b).  This indicates that the high dose 
formulation did not cause gross toxicities and the MET formulation thus enabled the 
administration of a higher dose, with the lack of uptake by the bone marrow and liver 
likely to limit the toxic effects (15, 28-30) that are normally observed with lomustine 
therapies.  
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Figure 9b (I and II): Body weight monitoring of female CD-1 mice bearing 
intracranial U-87 MG tumours following treatment with lomustine formulations: filled 
black symbols = MET lomustine (13 mg kg-1 per day, 2.6 mg mL-1, dose volume = ≈ 
200 µL, filled grey symbols = ethanolic lomustine (1.2 mg kg-1 per day, 0.18 mg mL-
1, dose volume = ≈ 200 µL), unfilled symbols = untreated control animals.  Body 
weights were not significantly different during the treatment phase of the 
experiment. 
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MRI analysis showed that tumour volumes for the MET lomustine formulation treated 
animals in the first study were significantly (p < 0.05) lower than those for the ethanolic 
formulation treated animals (Figure 10 a). However, there was an outlier with a tumour 
volume considerably larger than the others within the group of animals that had 
received the ethanolic formulation. This necessitated the conduct of the second 
experiment to confirm the findings from the first study. Analysis of the tumour volumes 
in the second experiment confirmed that tumour volumes for animals that received the 
MET lomustine formulation were generally lower than those of animals that received 
the ethanolic formulation and untreated control animals (Figure 10b). However, the 
differences were not statistically significant (p > 0.05).   
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Figure 10 a (top- first study) and b (bottom- second study): Tumour volumes for female 
CD-1 mice bearing intracranial U-87 MG tumours following treatment with lomustine 
formulations. QLOM = MET lomustine (13 mg kg-1 per day, 2.6 mg mL-1, dose volume 
= ≈ 200 µL, LOM-ETOH = ethanolic lomustine (1.2 mg kg-1 per day, 0.18 mg mL-1, 
dose volume = ≈ 200 µL), CONTROL = untreated control animals.   
 ̽ = Significantly different from MET lomustine (13 mg kg-1) formulation treated animals. 
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Discussion 
The MET formulation presented as a nanoemulsion in which the oil droplets are 
presumably coated with the MET polymer and polysorbate 80 (Figure 1).  The size 
distribution is heterogeneous and comprises micelles as well as oil droplets. The 
distribution of the two amphiphiles – the MET polymer and polysorbate 80 between the 
micelles and the oil droplets is unknown.  This formulation enables a higher dose to be 
administered as a bolus and this is in turn associated with a longer survival time 
(Figure 9a), when compared to the administration of the lomustine ethanolic – 
polysorbate 80 formulation at the maximum bolus dose possible.  However, it is the 
relatively reduced delivery of drug to the liver and bone (Figure 4, Tables 2 and 3) and 
the resultant minimal effect of the high dose formulation on myelosuppression (Figure 
6) that is the most interesting feature of the MET formulation. Lomustine  
chemotherapy is associated with dose limiting myelosuppression (15, 28-30) and 
autologous stem cell rescue (15).  Hepatotoxicity in dogs is also a feature of lomustine 
chemotherapy (31).  Myelosuppression and hepatotoxicity are thus dose limiting 
adverse effects for lomustine and any formulation that minimises bone marrow and 
liver exposure would have a positive impact on treatment and allow patients to take 
fewer treatment breaks, as the tumour would presumably continue to grow during such 
treatment breaks allowing the supporting microenvironment to recover rapidly.  
Lomustine is normally given orally and we administered it intravenously in this study, 
using it as a model drug to test the bone marrow sparing potential of the intravenous 
MET formulation. 
We have found that MET nanoparticles are taken up at a slower rate in vitro by mouse 
monocyte derived macrophage cell lines (Figure 7) and while these are not tissue 
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resident macrophages which have distinct functions, such as immune surveillance, 
removal of cell debris and iron processing (33), it is clear that these macrophages 
phagocytose liposomes more readily than when compared to the MET nanoparticles 
and we conclude that the surface chemistry of the MET particles must be responsible 
for their slower phagocytosis when compared to liposomes.  Such a conclusion is not 
without precedent as the exposure of phosphatidyl serine on the surface of apoptotic 
cells enables these cells to be taken up by tissue resident macrophages expressing 
the phosphatidyl serine receptor (33).  
It is possible that this reduced macrophage uptake is a key driver for the low bone and 
liver levels of the drug (Figure 4).  Low liver uptake of MET nanoparticles has been 
demonstrated in a number of studies (16, 35).  For example the coating of peptide 
nanofibres with the MET polymer resulted in a significant reduction in liver deposition 
(35), hence evidence is beginning to emerge in support of the hypothesis that the MET 
polymer coating diverts nanoparticles from the liver (Figure 4), spleen (16)  and bone 
marrow (Figure 4) on intravenous injection. While it is clear that there are correlations 
between macrophage uptake (Figure 7) and liver (Figure 4) and spleen (16) deposition 
of MET nanoparticles, when compared to liposomes (34) (Figure 7), we have not 
proven that the reduced macrophage uptake observed actually leads to reduced liver, 
spleen and bone marrow deposition of MET nanoparticles on intravenous injection, 
especially as tissue resident macrophages (which are proliferative and of embryonic 
origin) (33) were not used in our in vitro studies. 
To further understand the advantages offered by the liver/ bone sparing MET 
formulation, which in essence targets the drug to the brain, one must consider the fact 
that dose intensification would allow the drug to overwhelm the enzyme repair systems 
that confer resistance to the therapeutic, such as the enzyme O6-methylguanine-DNA 
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methyltransferase (MGMT), a DNA repair enzyme (7). Dose intensification, when tried 
in the clinic, although beneficial, is usually confounded by the toxicity of the regimen, 
most notably haematological toxicities (36).  In our studies, dose intensification with 
the MET formulation does not confer significant additional myelosuppressive effects 
when compared to the low dose ethanolic formulation and yet is therapeutically 
beneficial in this mouse intracranial tumour model. Dose intensification with the MET 
system definitely warrants clinical testing. 
Dose intensification with chemotherapy may be achieved either by increasing the dose 
or by increasing the frequency of dosing.  The  resulting haematological toxicities will 
take the form of neutropenia, thrombocytopenia or a reduction in red blood cells (36, 
37). Neutropenia, may lead to fatal infections and is the most frequently occurring toxic 
effect encountered with cytotoxic drugs (37). Due to the short life span (6 – 14 hours) 
(38) of granulocytes, they are usually the first to be negatively affected during 
chemotherapy (38). However, in the current study, the white blood cells were not 
affected by the high dose MET formulation and neither were the total bone marrow 
cells (Figures 6a and 6d). Platelets with a life span of 9 – 10 days in humans (39) and 
4 – 5 days in the mouse (40) are usually the next susceptible cell type to be affected 
by chemotherapy after the granulocytes (41). The results of the current study are 
consistent with this platelet vulnerability, as all treatment groups show a significant 
drop in platelet counts after 7 days, although platelets counts did revert to baseline 
levels after 14 and 21 days for the low dose ethanolic (1.2mg kg-1) and high dose MET 
(13 mg kg-1) formulations, respectively (Figure 6c).  
Toxic effects on the red blood cells are the last to be seen due to the longer life span 
of the erythrocytes with a life span of 100 – 120 days in humans (41, 42) and 30 – 52 
days in the mouse (40) and although there were minor drops recorded in the red cell 
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counts and haemoglobin levels in our studies, these changes in red blood cell counts 
and haemoglobin levels amount to no more than a 20 % change and thus are unlikely 
to be clinically significant.    
Conclusion 
Our findings show that lomustine dose intensification with the MET particle system 
improved the survival of intracranial tumour bearing mice and did not produce 
significant additional myelosuppressive effects as bone and bone marrow deposition 
of the drug was reduced with the MET system.  Liver deposition was also reduced with 
the MET system and since myelosuppression and liver toxicity are features of 
lomustine therapy, such a dose intensification strategy warrants clinical testing. 
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